Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. T. van Meerten

Publicaties

Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months

Real-World Accuracy of Continuous Glucose Monitoring During Intensive Hematological Care: A Prospective Study

Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans

Facts and hopes for PET imaging-derived immunotherapy biomarkers

High frequency of severe hyperglycemia observed during intensive hematological care: a prospective study using continuous glucose monitoring

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

Pers/media

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness

Subsidie voor onderzoek CAR-T-cellen voor mensen met multipel myeloom

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Gronings UMC gaat met overheidssubsidie zelf een prijzig buitenlands kankermedicijn maken

16,5 miljoen subsidie voor onderzoek CAR T-cellen bij beenmergkanker

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: 'Je wint tijd'

Dr van Meerten on the Efficacy and Safety of Brexu-Cel in BTK Inhibitor–Naive R/R MCL

Brexu-Cel Yields High Response Rates in Relapsed/Refractory, BTK-Naive MCL